The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

MemorialCare Saddleback Medical Center announced today that it is one of America's 250 Best Hospitals for 2025, according to ...

The robotics and automation industry in Germany has lost competitiveness: for 2025, it is forecasting a drop of minus 9 percent to 13.8 billion euros in total turnover. Last year, the sector closed ...

Colombian President Gustavo Petro says that his government won't accept flights carrying migrants deported from the United States until the Trump administration creates a protocol that treats them ...